Q3 EARNINGS: Abbott's devices a drag; Boston beats on revenues
This article was originally published in Clinica
Executive Summary
Abbott’s medical devices franchise was its worst-performing business, with sales falling 1%; but this did not dent the firm’s overall third-quarter results which fell in-line with expectations. Group Q3 revenues of $5.1bn from continuing operations were up 6% year-on-year; while revenues from both continuing and discontinued operations of $5.6bn met analyst predictions.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.